OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

In the era of telemedicine, see useful information on treating GBM with Optune. >>

Check out our wide range of resources for you, your practice, and your patients
with newly diagnosed GBM, designed to provide education on Optune. >>

SCROLL

PUT GBM ON PAUSE

PUT LIFE ON PLAY

Susan is
Brian’s caregiver.
Patient images reflect the health status of the
patients at the time each photo was taken.
Brian is an Optune
user and Patient
Ambassador.

OPTUNE HAS BEEN PROVEN TO

PROVIDE LONG-TERM QUALITY SURVIVAL

TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2

Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as a Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status. There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).

Optune is small and light, wearable and portable,
so it can be used almost anywhere1

JB is an Optune® user and Patient Ambassador JB is an Optune® user and Patient Ambassador

Optune Buddy Program
connects your patients with
an Optune user or caregiver

Your patients can ask questions and hear firsthand
experiences about starting and adjusting to Optune.
A video chat feature is also available.

"I was initially concerned
because I didn't fully understand what it
would be like. But, I overcame my fears ...
[and] in a matter of weeks,
I was at ease toting the backpack."

-JB, Optune user

"I was initially concerned

because I didn't fully understand what

it would be like. But, I overcame my

fears ... [and] in a matter of weeks,

I was at ease toting the backpack."

-JB, Optune user
Jeanneane, an Optune user and Patient Ambassador

Maintained
quality of life
 and
daily functioning
with Optune2

Optune® device components including easy-access sleeve bag, transducer arrays, electric field generator, and connection cable and box Optune® device components including easy-access sleeve bag, transducer arrays, electric field generator, and connection cable and box

Find out more
about Optune and
how to start patients
on treatment

*From a post hoc analysis.

The NCCN defines good performance as Karnofsky Performance Status (KPS) ≥60. The trial on which the IFU is based used an eligibility criteria of KPS ≥70.3,5
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. The 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.

References: 1. Optune. Instructions for Use for Glioblastoma Mutiforme. Novocure; 2019.
2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with Tumor-Treating Fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495–504. 3. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 4. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. 5. Referenced with permission from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed December 7, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).